Preimplantation Genetic Testing (PGT) Market Analysis

Preimplantation Genetic Testing Market Analysis

To get key market trends

  Download Free Sample

Based on product & service, the is segmented into products and services. The product segment dominated the market and is anticipated to grow at 9.3% CAGR over the forecast period.
 

• The product segment dominance was attributed as essential for conducting genetic screening in IVF procedures, as they include the reagents, sequencing kits, and testing consumables required for accurate testing of embryos.
   
• In addition, the rising incidence of genetic disorders and the increasing adoption of IVF fuels the need for these kits and consumables, further fueling the market demand.
   
• Additionally, advancements in NGS and other genetic technologies have led to the development of more efficient, high-precision kits, further increasing their demand.
   
• The recurring nature of consumables also ensures steady revenue generation, making this segment highly profitable.
   

Based on the technology the PGT market is categorized into next generation sequencing (NGS), polymerase chain reaction (PCR), fluorescent in-situ hybridization (FISH), array, and other technologies The NGS segment accounted for the highest market share of 42% in 2023.
 

• NGS technology's prominence was asserted due to its high accuracy, speed, and ability to analyze a broad range of genetic abnormalities.
   
• NGS allows for comprehensive screening of embryos, detecting both chromosomal aneuploidies and specific genetic mutations in a single test. Its ability to sequence multiple embryos simultaneously at a lower cost compared to traditional methods makes it highly efficient.
   
• As fertility clinics and researchers seek more precise results, the adoption of NGS in PGT has grown, driving its market leadership and fueling further advancements in reproductive technology.
   

Based on application, the preimplantation genetic testing market is segmented into aneuploidy screening, structural chromosomal rearrangement, monogenic/single-gene disorder screening, human leukocyte antigen (HLA) typing, and other applications. The aneuploidy screening segment is poised to reach USD 985.7 million by the end of 2032.
 

• Aneuploidy screening dominance was reflected in its widespread adoption among couples seeking to mitigate genetic risks.
   
• Aneuploidy, characterized by an abnormal number of chromosomes, is a leading cause of implantation failures and miscarriages.
   
• By identifying embryos with the correct chromosomal count, PGT-A significantly increases the chances of successful pregnancies and healthy births.
   
• For instance, according to a study conducted by Medpark Hospital, the success rates of PGT-A vary based on age and prior treatment. The study found that women undergoing IVF or ICSI who received PGT-A testing before embryo transfer achieved a remarkable 95% pregnancy success rate across three consecutive frozen embryo transfers. This highlighted the effectiveness of PGT-A in improving outcomes for couples seeking to ensure the health of their embryos, particularly in the context of advanced maternal age or previous reproductive challenges.
   
• Furthermore, the growing awareness of its benefits and advancements in genetic testing technologies further propel this segment's growth, making it a cornerstone of modern reproductive healthcare.
   

Based on end use, the preimplantation genetic testing market is segmented into hospitals & IVF clinics, diagnostic laboratories, fertility centers, and research institutes. The hospitals and IVF clinics segment dominated the market accounting for USD 328.9 million in 2023.
 

• Hospitals and IVF clinics drive significant growth in the market due to high patient volume, enhanced healthcare infrastructure, and the availability of IVF services in both public and private institutions.
   
• Families seeking fertility treatments frequently choose hospitals for their advanced technological capabilities. Additionally, increasing research activities in these facilities are expected to boost testing rates.
   

In 2023, the U.S. accounted for USD 312.2 million in the North American preimplantation genetic testing market and is expected to maintain its dominance throughout the forecast period.
 

• The U.S. prominence is attributed to its widespread adoption of advanced reproductive technologies, such as IVF, and the growing awareness of genetic screening.
   
• According to the U.S. Department of Health and Human Services, infertility affects millions of Americans at some point in their lives. IVF is a crucial fertility treatment, accounting for over 99% of ART procedures. In 2021, approximately 86,146 infants, or 2.3% of all births in the U.S., were conceived through ART, with around 16.6% of these cases involving PGT. The rising prevalence of infertility, combined with increasing awareness of advanced technologies for early diagnosis of disorders, further reinforces the U.S. position in the market.
   
• The U.S. is home to leading fertility clinics and companies offering advanced PGT technologies, further solidifying its dominance in the region's market and driving overall growth.
   

China has experienced the fastest growth in the preimplantation genetic testing market within the Asia-Pacific region.
 

• The growth is attributed to increasing infertility rates and rising awareness of advanced reproductive technologies. The growing number of fertility clinics and enhanced healthcare infrastructure have facilitated greater access to IVF and genetic testing services.
   
• Supportive government policies promoting ART further contribute to this expansion, positioning China as a key player in the Asia Pacific market and driving demand for innovative genetic screening solutions.
   

Germany holds a prominent position in the Europe preimplantation genetic testing market.
 

• Germany's position is driven by its advanced healthcare infrastructure and robust regulatory framework.
   
• The country benefits from increasing public awareness of genetic disorders and the advantages of PGT, encouraging more couples to pursue genetic testing as part of their reproductive planning.
   
• Germany's well-established fertility clinics and access to advanced reproductive technologies further support market growth.
   
• Favorable regulations regarding aneuploidy screening enhance the acceptance and utilization of PGT services, solidifying Germany's role as a leader in this sector within Europe.
   

Saudi Arabia holds a significant share in the Middle East and Africa preimplantation genetic testing market.
 

• Saudi Arabia's position is due to several factors, including increasing awareness of reproductive health and advancements in ART.
   
• The country has invested in modern healthcare infrastructure, with numerous fertility clinics offering PGT services to address rising infertility rates.
   
• Cultural shifts towards family planning and the desire for healthier pregnancies have driven demand for genetic testing. These elements collectively enhance Saudi Arabia's prominence in the region's PGT market, positioning it as a key player in advancing reproductive health solutions.